Who is sponsoring NCT03552796?

NCT03552796 is sponsored by University of Southern California.

What drugs are being tested in NCT03552796?

Interventions in NCT03552796: Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein.

What condition does NCT03552796 study?

NCT03552796 studies Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I.

Is NCT03552796 still recruiting?

NCT03552796 is currently withdrawn. Last updated 26 June 2023.

Last reviewed 2023-06-26 · How we verify

NCT03552796

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Withdrawn Phase 1 Last updated 26 June 2023

What this trial tests

Phase 1 trial testing Pharmacokinetic Study in Recurrent Bladder Carcinoma. Withdrawn.

Timeline

1 August 2023

Primary endpoint
1 August 2024

1 August 2025

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 August 2023
Primary completion	1 August 2024
Estimated completion	1 August 2025
Sites	1 location across United States

Drugs / interventions tested

Pharmacokinetic Study
Recombinant EphB4-HSA Fusion Protein — full drug profile →

Conditions studied

Recurrent Bladder Carcinoma — all drugs for Recurrent Bladder Carcinoma →
Bladder Cancer Stage 0 — all drugs for Bladder Cancer Stage 0 →
Bladder Cancer Stage I — all drugs for Bladder Cancer Stage I →

Sponsor

University of Southern California

Who can join

Adults 18 to 80, any sex, with Recurrent Bladder Carcinoma or Bladder Cancer Stage 0. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding to bacillus Calmette-Guerin (BCG) vaccine treatment. sEphB4-HAS prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. Giving sEphB4-HSA may work better in treating participants with bladder cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.
Mu X, Huang O, Jiang M, Xie Z, et al · · 2019 · cited 4× · PMID 31289549 · DOI 10.3892/ol.2019.10363

Verify or expand the search:

Other trials of Pharmacokinetic Study

Trials testing the same drug.

NCT05627245 — Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Tr · Phase 1 · active not recruiting
NCT03542695 — 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergo · EARLY_PHASE1 · completed
NCT03259503 — Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Tran · Phase 1 · completed
NCT03756818 — TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors · Phase 1 · completed
NCT03698994 — Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pa · Phase 2 · active not recruiting

Other recruiting trials for Recurrent Bladder Carcinoma

Currently open trials in the same condition.

NCT06733363 — A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscl · Phase 2 · recruiting
NCT03047213 — Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations · Phase 2 · active not recruiting
NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M · Phase 2 · active not recruiting

Other University of Southern California trials

Trials by the same sponsor.

NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552796 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 26 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552796.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing